Intended for healthcare professionals


Eli Lilly defends itself against assertions in BMJ

BMJ 2005; 330 doi: (Published 20 January 2005) Cite this as: BMJ 2005;330:161
  1. Jeanne Lenzer
  1. New York

    The drug company Eli Lilly has launched a campaign to refute assertions about its anti-depressant medicine, fluoxetine (Prozac), made in an article in the BMJ (2005:330: 7, 1 Jan) about internal company documents sent to the BMJ by an anonymous source.

    Sydney Taurel, Lilly's chief executive, in an open letter published in the Wall Street Journal on 13 January, wrote that the BMJ article and the misleading reports about it in other media have “needlessly spread fear among patients who take Prozac.”

    In response to the suggestion that Lilly might not have reported negative data to the Food and Drug Administration or the …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription